TES Pharma - Crunchbase Company Profile & Funding

Q: Where is TES Pharma's headquarters?

TES Pharma is located in Perugia, Umbria, Italy.

Q: Who invested in TES Pharma?

TES Pharma has 3 investors including Indaco Venture Partners And XGEN Venture.

Q: When was the last funding round for TES Pharma?

TES Pharma closed its last funding round on obfuscated from a Series A round.

Q: How much funding has TES Pharma raised to date?

TES Pharma has raised obfuscated.

Overview

TES Pharma

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About TES Pharma

CB Rank

72691

TES Pharma is a research-based biopharmaceutical company.

Founded

obfuscation

Private

Series A

Perugia, Umbria, Italy

11-50

www.tespharma.com

Biotechnology

Delivery

Pharmaceutical

Therapeutics

Funding Rounds

Series A

OBF

obfuscation

Series A

OBF

obfuscation

Details

Legal Name

TES Pharma srl

Operating Status

Active

Company Type

For Profit

About the Company

TES Pharma is a research-based biopharmaceutical company focusses on delivering first in class preclinical candidates that unlock the potential of novel therapeutic targets and mechanisms.

Phone Number

+39 075 697 8111

Contact Email

info@tespharma.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Runway Speculation

Products & Services

TES-AKI-01

A small molecule inhibitor targeting the ACMSD enzyme to treat acute kidney injury by restoring NAD+ levels and improving kidney function.

INT-787

A Farnesoid X Receptor (FXR) agonist in clinical development for severe alcohol-associated hepatitis, licensed to Intercept Pharmaceuticals.

Research & Development

TES Pharma is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - TES Pharma	1	obfuscated obfuscation	Indaco Venture Partners	Series A
obfuscated obfuscation	Series A - TES Pharma	1	obfuscated obfuscation	Indaco Venture Partners	Series A
obfuscated obfuscation	Series A - TES Pharma	1	obfuscated obfuscation	Indaco Venture Partners	Series A
obfuscated obfuscation	Series A - TES Pharma	1	obfuscated obfuscation	Indaco Venture Partners	Series A
obfuscated obfuscation	Series A - TES Pharma	1	obfuscated obfuscation	Indaco Venture Partners	Series A

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - TES Pharma	1	obfuscated obfuscation	Indaco Venture Partners	Series A
obfuscated obfuscation	Series A - TES Pharma	1	obfuscated obfuscation	Indaco Venture Partners	Series A
obfuscated obfuscation	Series A - TES Pharma	1	obfuscated obfuscation	Indaco Venture Partners	Series A
obfuscated obfuscation	Series A - TES Pharma	1	obfuscated obfuscation	Indaco Venture Partners	Series A
obfuscated obfuscation	Series A - TES Pharma	1	obfuscated obfuscation	Indaco Venture Partners	Series A

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Indaco Venture Partners	Yes	Series A - TES Pharma	Davide Turco, Giovanni Rizzo
Indaco Venture Partners	Yes	Series A - TES Pharma	Davide Turco, Giovanni Rizzo
Indaco Venture Partners	Yes	Series A - TES Pharma	Davide Turco, Giovanni Rizzo
Indaco Venture Partners	Yes	Series A - TES Pharma	Davide Turco, Giovanni Rizzo
Indaco Venture Partners	Yes	Series A - TES Pharma	Davide Turco, Giovanni Rizzo